Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
199
datasets available to search
ShareScore release 0.9.0
Dataset results
199 results for “CASE REPORT”
Stroke risk, phenotypes, and death in COVID-19: systematic review and newly reported cases
Open the record for dataset details and reuse information.
Data from: A reference set of curated biomedical data and metadata from clinical case reports
Open the record for dataset details and reuse information.
Improving Traceability Recovery Between Bug Reports and Manual Test Cases
<p>Vídeo backup da apresentação SBES 2020.</p> <p>Artigo: Improving Traceability Recovery Between Bug Report and Manual Test Cases.</p>
Data from: Calculating maximum morphine equivalent daily dose from prescription directions for use in the electronic health record: a case report
Objective To demonstrate a process of calculating the maximum potential morphine milligram equivalent daily dose (MEDD) based on the prescription Sig for use in quality improvement initiatives. Methods To calculate an opioid prescription's maximum potential Sig-MEDD, we developed SQL code to determine a prescription's maximum units/day using discrete field data and text-parsing in the prescription instructions. We validated the derived units/day calculation using 3,000 Sigs, then compared the Sig-MEDD calculation against the Epic MEDD calculator. Results Of the 101,782 outpatient opioid prescriptions ordered over one year, 80% used discrete-field Sigs, 7% used free-text Sigs, and 3% used both types. We determined units/day and calculated a Sig-MEDD for 98.3% of all prescriptions, 99.99% of discrete-Sig prescriptions, and 81.5% of free-text-Sig prescriptions. Conclusion Analyzing opioid prescription Sigs to determine a maximum potential Sig-MEDD provides greater insight into a patient's risk for opioid exposure.
A vigiPoint characterisation of female versus male reports in VigiBase, the WHO global database of individual case safety reports
<p><strong>General information</strong></p> <p>This data is supplementary material to the paper by Watson <em>et al</em>. on sex differences in global reporting of adverse drug reactions [1]. Readers are referred to this paper for a detailed description of the context in which the data was generated. Anyone intending to use this data for any purpose should read the publicly available information on the VigiBase source data [2, 3]. The conditions specified in the caveat document [3] must be adhered to.</p> <p><b>Source dataset</b></p> <p>The dataset published here is based on analyses performed in VigiBase, the WHO global database of individual case safety reports [4]. All reports entered into VigiBase from its inception in 1967 up to 2 January 2018 with patient sex coded as either female or male have been included, except suspected duplicate reports [5]. In total, the source dataset contained 9,056,566 female and 6,012,804 male reports.</p> <p><strong>Statistical analysis</strong></p> <p>The characteristics of the female reports were compared to those of the male reports using a method called vigiPoint [6]. This is a method for comparing two or more sets of reports (here female and male reports) on a large set of reporting variables, and highlight any feature in which the sets are different in a statistically and clinically relevant manner. For example, patient age group is a reporting variable, and the different age groups 0 - 27 days, 28 days - 23 months et cetera are features within this variable. The statistical analysis is based on shrinkage log odds ratios computed as a comparison between the two sets of reports for each feature, including all reports without missing information for the variable under consideration. The specific output from vigiPoint is defined precisely below. Here, the results for 18 different variables with a total of 44,486 features are presented. 74 of these features were highlighted as so called vigiPoint key features, suggesting a statistically and clinically significant difference between female and male reports in VigiBase.</p> <p><strong>Description of published dataset</strong></p> <p>The dataset is provided in the form of a MS Excel spreadsheet (.xlsx file) with nine columns and 44,486 rows (excluding the header), each corresponding to a specific feature. Below follows a detailed description of the data included in the different columns.</p> <p><em>Variable</em>: This column indicates the reporting variable to which the specific feature belongs. Six of these variables are described in the original publication by Watson <em>et al</em>.: <em>country of origin</em>, <em>geographical region of origin</em>, <em>type of reporter</em>, <em>patient age group</em>, <em>MedDRA SOC</em>, <em>ATC level 2 of reported drugs</em>, <em>seriousness</em>, and <em>fatality </em>[1]. The remaining 12 are described here:</p> <ul> <li> <em>MedDRA HLGT</em> (high-level group term), <em>MedDRA HLT </em>(high-level term) and <em>MedDRA PT</em> (preferred term) are defined analogously to the <em>MedDRA SOC</em> (system organ class) [1], only at lower levels of the <a href="https://www.meddra.org/">MedDRA </a>(Medical Dictionary for Regulatory Activities) hierarchy. Here, MedDRA version 20.1 has been used.</li> <li> <em>ATC level 3 of reported drugs</em> is defined analogously to the variable <em>ATC level 2 of reported drugs </em>[1], only one step further down in the <a href="https://www.whocc.no/atc/structure_and_principles">ATC</a> (Anatomical Therapeutical Classification) hierarchy.</li> <li>The vigiGrade <i>completeness score</i> is a measure of how complete each report is with respect to certain report fields useful for causality assessment [7]. The completeness score has been dichotomised into two features, 'Above or equal to 0.8' and 'Below 0.8'. The maximum possible score for an individual report is 1.0.</li> <li>The <em>date of VigiBase entry </em>is simply the time when a report was entered into VigiBase. This variable is divided into 14 features that are either individual years or ranges of years.</li> <li> The <em>number of reported drugs</em> is the number of unique drugs that are coded on a report as either suspected, interacting, or concomitant. A drug is here defined as an entry at the preferred base (i.e. substance) level of the WHODRUG terminology. The variable is divided into four features: 'One drug', 'Two drugs', '3-5 drugs', and 'More than 5 drugs'.</li> <li> The <em>number of reported MedDRA PTs</em> is the number of unique MedDRA preferred terms that are coded as events on a report. This variable is divided into four features in exactly the same way as the reported drugs.</li> <li> A <i>reported drug</i> is a drug coded on a report as either suspected, interacting, or concomitant. As above, a drug is defined as an entry at the preferred base (i.e. substance) level of the WHODRUG terminology. This variable has almost 23,000 features, one for each drug that occurs in at least one female or one male report.</li> <li> The <em>type of report</em> indicates the type of individual case report. The vast majority belongs to the feature 'Spontaneous', but there are four other possible features for this variable.</li> </ul> <p>The <em>Variable </em>column can be useful for filtering the data, for example if one is interested in one or a few specific variables.</p> <p><i>Feature: </i>This column contains each of the 44,486 included features. The vast majority should be self-explanatory, or else they have been explained above, or in the original paper [1].</p> <p><em>Female reports</em> and <em>Male reports</em>: These columns show the number of female and male reports, respectively, for which the specific feature is present.</p> <p><em>Proportion among female reports</em> and <em>Proportion among male reports</em>: These columns show the proportions within the female and male reports, respectively, for which the specific feature is present. Comparing these crude proportions is the simplest and most intuitive way to contrast the female and male reports, and a useful complement to the specific vigiPoint output.</p> <p><em>Odds ratio</em>: The odds ratio is a basic measure of association between the classification of reports into female and male reports and a given reporting feature, and hence can be used to compare female and male reports with respect to this feature. It is formally defined as <em>a / (bc / d)</em>, where</p> <ul> <li> <em>a</em> is the number of female reports with the feature</li> <li> <em>b</em> is the number of female reports without the feature (excluding reports where the variable is missing)</li> <li> <em>c</em> is the number of male reports with the feature</li> <li> <i>d</i> is the number of male reports without the feature (excluding reports where the variable is missing).</li> </ul> <p>This crude odds ratio can also be computed as <em>(p<sub>female</sub> / (1-p<sub>female</sub>)) / (p<sub>male</sub> / (1-p<sub>male</sub>))</em>, where <em>p<sub>female</sub></em> and <em>p<sub>male</sub></em> are the proportions described earlier. If the odds ratio is above 1, the feature is more common among the female than the male reports; if below 1, the feature is less common among the female than the male reports. Note that the odds ratio can be mathematically undefined, in which case it is missing in the published data.</p> <p><em>vigiPoint score</em>: This score is defined based on an odds ratio with added statistical shrinkage, defined as (<em>a + k) / ((bc / d) + k)</em>, where <em>k</em> is 1% of the total number of female reports, or about 9,000. While the shrinkage adds robustness to the measure of association, it makes interpretation more difficult, which is why the crude proportions and unshrunk odds ratios are also presented. Further, 99% credibility intervals are computed for the shrinkage odds ratios, and these intervals are transformed onto a log<sub>2</sub> scale [6]. The vigiPoint score is then defined as the lower endpoint of the interval, if that endpoint is above 0; as the higher endpoint of the interval, if that endpoint is below 0; and otherwise as 0. The vigiPoint score is useful for sorting the features from strongest positive to strongest negative associations, and/or to filter the features according to some user-defined criteria.</p> <p><em>vigiPoint key feature</em>: Features are classified as vigiPoint key features if their vigiPoint score is either above 0.5 or below -0.5. The specific thereshold of 0.5 is arbitrary, but chosen to identify features where the two sets of reports (here female and male reports) differ in a clinically significant way.</p> <p><strong>References</strong></p> <ol> <li>Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a decade. <em>EClinicalMedicine</em> 2019.</li> <li>Uppsala Monitoring Centre. <a href="https://www.who-umc.org/media/164772/guidelineusingvigibaseinstudies.pdf">Guideline for using VigiBase data in studies</a>.</li> <li>Uppsala Monitoring Centre. <a href="https://www.who-umc.org/media/164610/umc_caveat.pdf">Caveat document: Statement of reservations, limitations, and conditions relating to data released from VigiBase, the WHO global database of individual case safety reports (ICSRs)</a>.</li> <li>Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. <i>The Drug Information Journal</i> 2008; <b>42</b>(5): 409-19.</li> <li>Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. <em>Data Mining and Knowledge Discovery</em> 2007; <strong>14</strong>(3): 305-28.</li> <li>Juhlin K, Star K, Norén GN. A method for data-driven exploration to pinpoint key features in medical data and facilitate expert review. <i>Pharmacoepidemiology and Drug Safety</i> 2017; <b>26</b>(10): 1256-65.</li> <li>Bergvall T, Norén GN, Lindquist M. vigiGrade: A tool to identify well-documented individual case reports and highlight systematic data quality issues. <em>Drug Safety </em>2014; <strong>37</strong>(1): 65-77.</li> </ol>
Measurement report: Impact of emission control measures on environmental persistent free radicals and reactive oxygen species – A short-term case study in Beijing
Open the record for dataset details and reuse information.
Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
Open the record for dataset details and reuse information.
Patient with aberrant internal carotid artery in the middle ear presenting with rare symptoms of mixed hearing loss and postauricular pain: a case report
<p>Video of otoscopy of aberrant internal carotid artery in the middle ear</p>
Kludt et al. Cell Reports Medicine - Biopsy cases WNS - PART 2
<p>Anonymized whole slide images to WNS cohort biopsy cases (PART 2) from the publication:</p> <p>"Next generation lung cancer pathology: development and validation of diagnostic and prognostic algorithms"</p> <p>in Cell Reports Medicine 2024</p> <p> </p> <p>The ground truth for subtype information is included.</p> <p><br>The dataset can be used for academic research purposes only.</p> <p> </p> <p>(c) Yuri Tolkach</p>
Kludt et al. Cell Reports Medicine - Biopsy cases UKK - PART 2
<p>Anonymized whole slide images to UKK cohort biopsy cases (PART 2) from the publication:</p> <p>"Next generation lung cancer pathology: development and validation of diagnostic and prognostic algorithms"</p> <p>in Cell Reports Medicine 2024</p> <p> </p> <p>The ground truth for subtype information is included.</p> <p><br>The dataset can be used for academic research purposes only.</p> <p> </p> <p>(c) Yuri Tolkach </p>
Kludt et al. Cell Reports Medicine - Biopsy cases UKK - PART 1
<p>Anonymized whole slide images to UKK cohort biopsy cases (PART1) from the publication:</p> <p>"Next generation lung cancer pathology: development and validation of diagnostic and prognostic algorithms"</p> <p>in Cell Reports Medicine 2024</p> <p> </p> <p>The ground truth for subtype information is included.</p> <p><br>The dataset can be used for academic research purposes only.</p> <p> </p> <p>(c) Yuri Tolkach </p>
Kludt et al. Cell Reports Medicine - Biopsy cases WNS - PART 1
<p>Anonymized whole slide images to WNS cohort biopsy cases (PART 1) from the publication:</p> <p>"Next generation lung cancer pathology: development and validation of diagnostic and prognostic algorithms"</p> <p>in Cell Reports Medicine 2024</p> <p> </p> <p>The ground truth for subtype information is included.</p> <p><br>The dataset can be used for academic research purposes only.</p> <p> </p> <p>(c) Yuri Tolkach </p>
Kludt et al. Cell Reports Medicine - Challenging Subtyping Cases (Biopsy)
<p>Anonymized whole slide images to challenging biopsy cases from the publication:</p> <p>"Next generation lung cancer pathology: development and validation of diagnostic and prognostic algorithms"</p> <p>in Cell Reports Medicine 2024</p> <p>The ground truth information is included.</p> <p><br>The dataset can be used for academic research purposes only.</p> <p> </p> <p>(c) Yuri Tolkach<br> </p>
Kludt et al. Cell Reports Medicine - Challenging Subtyping Cases (Resection)
<p>Anonymized whole slide images to challenging resection cases from the publication:</p> <p>"Next generation lung cancer pathology: development and validation of diagnostic and prognostic algorithms"</p> <p>in Cell Reports Medicine 2024</p> <p>The ground truth information is included.</p> <p> </p> <p>The dataset can be used for academic research purposes only. </p> <p> </p> <p>(c) Yuri Tolkach</p>
Fig. 1 in First Report of a Case of Prostatitis Due to Acanthamoeba in a Dog
Fig. 1. Echography of the prostate showing alteration of the pros- tatic parenchyma, with various irregular anechoic foci and multiple hyperechoic dotted pattern with non-defined margins.
Fig. 3. Acanthamoeba specific PCR using JDP1 in First Report of a Case of Prostatitis Due to Acanthamoeba in a Dog
Fig. 3. Acanthamoeba specific PCR using JDP1/JDP2 primers. Lane 1: Molecular Weight Marker 100bp ladder; Lane 2: Prostate Fluid; Lane 3: Non-Nutrient Agar Amoebic Culture; Lane 4: Axenic culture; Lane 5: Positive control Acanthamoeba castellani Neff ATCC 30010 DNA; Lane 6: Negative control, bidistilled water.
Fig. 4 in Cryptosporidium cf. avium in an inland-bearded dragon (Pogona vitticeps) - A case report and review of the literature
Fig. 4. Relationship of the novel Cryptosporidium cf. avium taxa (in bold) from the faeces of the inland-bearded dragon with representative Cryptosporidium sequences, established based on a phylogenetic analysis of sequence data from concatenated SSU and actin genes employing the neighbour-joining distance method. Branch supports are represented by neighbour-joining bootstrap percentages. C. andersoni was used as an outgroup.
Laparoscopic Anatomical S7 Segmentectomy by the Inferior Right Hepatic Veins First Approach: A Video Case Report
Open the record for dataset details and reuse information.
Thoracolumbar Interfascial Plane Block (TLIP) Modified Technique for Lumbar Decompression Surgery in Cirrhotic Hepatic Patients with Thrombocytopenia: A Case Report
<p><strong>Christella Natali</strong><strong>, </strong><strong>Erlina Soebroto</strong><strong>, </strong><strong>Komang Ayu Ferdiana</strong></p> <p>Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia</p>
Relationship Disappointment Stress Syndrome and Ubuntu Centred Therapy: Case report
<p>This is a data set for the manuscript submitted </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.